ARYA Sciences Acquisition Corp V
| IPO Proceeds, $M | $149.50M |
|---|---|
| IPO Date | Jul 13, 2021 |
| CEO | Adam Stone |
| Left Lead | Jefferies |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
North American or European companies in the life sciences and medical technology sectors |
| IPO Geography | Global |
| Target Company | N/A |
| Deal Announced | N/A |
| Deal Size, $M | TBD |
| Deal Sector | TBD |
| Deal Geography | TBD |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | TBD |
| Closing Date | Jul 17, 2023 |
| Price | |
|---|---|
| Volume, 3-month avg. | N/A |
No credit card required
Sign in for more on ARYA Sciences Acquisition Corp V:
- Structure and cap table
- 8 directors & officers
- 6 filings and events
- 2 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Joseph Edelman | 65 | Chairman |
| Adam Stone | 41 | Chief Executive Officer and Director |
| Michael Altman | 39 | Chief Financial Officer and Director |
| Konstantin Poukalov | 37 | Chief Business Officer |
| Todd Wider | 56 | Director |
| Jake Bauer | 42 | Director |
| Sanjiv K. Patel | 48 | Director |
| Debra Yu | 56 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
| Jefferies | Joint BR | 6,500,000 | units |
| Goldman Sachs | Joint BR | 6,500,000 | |
| 13,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Filings
| Jun 24, 2021 | Initial S-1 |
| Jul 12, 2021 |
PR announcing pricing of $130mm IPO
Sign In to view filing content. |
| Jul 14, 2021 | 424B4 IPO Prospectus |
| Jul 15, 2021 |
8-K announcing full over-allotment exercise
Sign In to view filing content. |
| Jun 13, 2023 |
PRE14A Preliminary Proxy for charter extension meeting
Sign In to view filing content. |
| Jul 3, 2023 |
8-K announcing liquidation and redemption of public shares
Sign In to view filing content. |